Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) reached a new 52-week high on Monday . The company traded as high as $132.79 and last traded at $130.4810, with a volume of 22646 shares changing hands. The stock had previously closed at $131.62.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on PTGX shares. Barclays upped their price target on Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, March 19th. Citizens Jmp raised their price objective on Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Truist Financial lifted their price objective on shares of Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Johnson Rice reiterated a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Finally, Wall Street Zen downgraded shares of Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $115.21.
Check Out Our Latest Stock Report on PTGX
Protagonist Therapeutics Price Performance
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The business had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. On average, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current year.
Insiders Place Their Bets
In other news, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the sale, the director directly owned 7,825 shares in the company, valued at $922,880.50. The trade was a 53.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total transaction of $7,509,000.00. Following the transaction, the chief executive officer owned 523,478 shares of the company’s stock, valued at approximately $52,410,617.36. The trade was a 12.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 162,880 shares of company stock valued at $16,539,792. 5.19% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Protagonist Therapeutics
Large investors have recently modified their holdings of the stock. Farther Finance Advisors LLC lifted its stake in Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the last quarter. Greenline Wealth Management LLC purchased a new position in shares of Protagonist Therapeutics during the 4th quarter valued at $27,000. EverSource Wealth Advisors LLC increased its holdings in Protagonist Therapeutics by 138.9% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after acquiring an additional 314 shares during the last quarter. Osaic Holdings Inc. raised its stake in Protagonist Therapeutics by 79.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock valued at $65,000 after acquiring an additional 525 shares during the period. Finally, Hantz Financial Services Inc. lifted its holdings in Protagonist Therapeutics by 222.4% during the fourth quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock valued at $83,000 after purchasing an additional 656 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.
Featured Stories
- Five stocks we like better than Protagonist Therapeutics
- AI Is Selling Off, But These 5 Stocks Could Benefit Next
- These 3 Stocks Offer Investors Exposure to the Functional Beverage Boom
- Alcoa’s $4.1 Billion South32 Deal: Opportunity Behind the 9% Drop
- 3 High-Yield Dividend Stocks With Real Capital Gains Potential in 2026
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
